Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
This study aimed to determine whether and how the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide affects the chemoresistance and chemosensitivity of pancreatic cancer cells to gemcitabine in vitro and in vivo. The GLP-1R and protein kinase A (PKA) levels were compared between the human pancreatic cancer cell line PANC-1 and the gemcitabine-resistant cell line PANC-GR. The in vitro effects of liraglutide on the cell proliferation and apoptosis as well as the nuclear factor-kappa B NF-κB expression levels of PANC-GR cells were evaluated. In addition, a mouse xenograft model of human pancreatic cancer was established by s.c. injection of PANC-1 cells, and the effects of liraglutide on the chemosensitivity were evaluated in vitro and in vivo. In contrast to PANC-1 cells, PANC-GR cells exhibited lower expression levels of GLP-1R and PKA. Incubation with liraglutide dose dependently inhibited the growth, promoted the apoptosis, and increased the expression of GLP-1R and PKA of PANC-GR cells. Similar effects of liraglutide were observed in another human pancreatic cancer cell line MiaPaCa-2/MiaPaCa-2-GR. Either the GLP-1R antagonist Ex-9, the PKA inhibitor H89, or the NF-κB activator lipopolysaccharide (LPS) could abolish the antiproliferative and proapoptotic activities of liraglutide. Additionally, each of these agents could reverse the expression of NF-κB and ABCG2, which was decreased by liraglutide treatment. Furthermore, liraglutide treatment increased the chemosensitivity of pancreatic cancer cells to gemcitabine, as evidenced by in vitro and in vivo experiments. Thus, GLP-1R agonists are safe and beneficial for patients complicated with pancreatic cancer and diabetes, especially for gemcitabine-resistant pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
NF-κB, Inflammation, and Metabolic Disease
Baker, R. G., Hayden, M. S., & Ghosh, S. (2011) · Cell Metabolism · doi:10.1016/j.cmet.2010.12.008 · Cited by 1,952
Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control
Lee, Y.-S., & Jun, H.-S. (2016) · Mediators of Inflammation · doi:10.1155/2016/3094642 · Cited by 530
GLP-1 Receptor Expression in Human Tumors and Human Normal Tissues: Potential for In Vivo Targeting
Korner, M., Stockli, M., Waser, B., & Reubi, J. C. (2007) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.038679 · Cited by 477
Gemcitabine Resistance in Pancreatic Cancer: Picking the Key Players
Kim, M. P., & Gallick, G. E. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2247 · Cited by 177
Prevalence of Diabetes Mellitus in Pancreatic Cancer Compared to Common Cancers
Aggarwal, G., Kamada, P., & Chari, S. T. (2013) · Pancreas · doi:10.1097/mpa.0b013e3182592c96 · Cited by 167 · cited 1×
“Patients with pancreatic cancer have a high prevalence of diabetes mellitus (68%), and glycemic control affects the prognosis of patients with pancreatic cancer (Aggarwal et al. 2013).”
BackgroundZhu, T., Wu, X.-L., Zhang, W., & Xiao, M. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160920195 · Cited by 106
Zhao, H., Wang, L., Wei, R., Xiu, D., Tao, M., Ke, J., Liu, Y., Yang, J., & Hong, T. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12291 · Cited by 88
Self-citation
Cited by
GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
Zhao, X., Wang, M., Wen, Z., Lu, Z., Cui, L., Fu, C., Xue, H., Liu, Y., & Zhang, Y. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.721135 · Cited by 463
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10192-9 · Cited by 56
Ma, B., Wang, X., Ren, H., Li, Y., Zhang, H., Yang, M., & Li, J. (2023) · BMC Cancer · doi:10.1186/s12885-023-11077-w · Cited by 36
Kim, M., Kim, S. C., Kim, J., & Kim, B. H. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0105 · Cited by 26
“Similarly, liraglutide has demonstrated significant antiproliferative and pro-apoptotic effects in gemcitabine-re-sistant human pancreatic cancer cells, enhancing their chemo-sensitivity in both in vitro and in vivo experiments [35].”
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Metadata
- Authors
- Zhao, H.-J., Jiang, X., Hu, L.-J., Yang, L., Deng, L.-D., Wang, Y.-P., & Ren, Z.-P.
- Venue
- Journal of Molecular Endocrinology
- Publisher
- Bioscientifica
- Published
- 2020-02
- Volume
- 64
- Issue
- 2
- Pages
- 103-113
- ISSN
- 0952-5041 (ISSN-L)
- 1479-6813
- OpenAlex
- W2995294181
- Cited by
- 43
- References
- 7
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells. https://app.cochat.ai/papers/10.1530/jme-19-0186
- The paper
- Zhao, H.-J., Jiang, X., Hu, L.-J., Yang, L., Deng, L.-D., Wang, Y.-P., & Ren, Z.-P. (2020). Activation of GLP-1 receptor enhances the chemosensitivity of pancreatic cancer cells. Journal of Molecular Endocrinology. https://doi.org/10.1530/jme-19-0186
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.